Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1994-02-04
1997-11-11
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 51, 514120, A61K 3170, A61K 3166
Patent
active
056864280
ABSTRACT:
Combinations of 3'-azido-3'deoxythymidine and phsphonoformate have been found to produce a synergistic inhibitory effect against human immunodeficiency virus (HIV).
REFERENCES:
patent: 4724232 (1988-02-01), Rideout et al.
patent: 4857511 (1989-08-01), Rideout et al.
Bertil F. H. Eriksson and Raymond F. Schinazi, Combinations of 3'-Azido -3'-Deoxythymidine (Zidoundine) . . . Antimicrobial Agents & Chemotherapy, vol. 33, No. 5, pp. 663-669, (May 1989).
Eriksson, B.G., et al., "Inhibition of Reverse Transcriptase Activity of Avian Myeloblastosis Virus by Pyrophosphate Analogues", Antiviral Res., 2:81-95 (1982).
Eriksson, B., et al., "Different Patterns of Inhibition of Avian Myeloblastosis Virus Reverse Transcriptase Activity by 3'-Azido-3'-Deoxythymidine-5'-Triphosphate and its thero Isomer," Antimicrob. Agents Chemother., 31:(1987) 600-604.
Farthing, C., et al., "Treatment of Cytomegalovirus Pneumonitis with Foscarnet (Trisodium Phosphonoformate) in Patients with AIDS," J. Med. Virol. 22:157-162 (1987).
Farthing, C.F., et al., "Phosphonoformate (Foscarnet): A Pilot Study in AIDS and AIDS Related Complex," AIDS 1: (1987) 21-25.
Field, A.K., et al., "`The End of Innocence` Revisited: Resistance of Herpesviruses to Antiviral Drugs," Clin. Microb., Rev. 7: (1964) l-13.
Fischer, A.G., et al., "Biologically Diverse Molecular Variants within a Single HIV-1 Isolate," Nature, 334:444-447 (1988).
Fischl, M.A., et al., "The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex. A Double-Blind, Placebo-Controlled Trial," New Engl. J. Med., 317:185-191 (1987).
Fletcher, C.V., et al., "Foscarent for the Suppression of Human Immunodeficiency Virus Replication," Antimicrob. Agents Chemother., 38: (1994) 604-607.
Frank, K.B., et al., "Mutually Exclusive Inhibition of Herpesvirus DNA Polymerase by Aphidicolin, Phosphonoformate, and Acyclic Nucleoside Triphosphates," Antimicrob. Agents Chemother. 27:445-448 (1985).
Furman, P.A., et al., "Phosphorylation of 3'-Azido-3'-Deoxythymidine and Selective Interaction of the 5'-Triphosphate with Human Immunodeficiency Virus Reverse Transcriptase," Proc. Natl. Acad. Sci. USA 83:8333-8337 (1986).
Gaub, J., et al., "The Effect of Foscarnet (Phosphonoformate) on Human Immunodeficiency Virus Isolation, T-Cell Subsets and Lymphocyte Function in AIDS Patients," AIDS 1:1 27-33 (1987).
Hall, M.J., et al., "Antiviral Drugs and Interferon Combinations," pp. 29-84 in J.H. Field (ed.) Antiviral Agents: The Development and Assessment of Antiviral Chemotherapy vol. II, CRC Press, Inc., Boca Raton, Florida (1988).
Hammer, S.H., et al., "Synergistic Activity of Granulocytemacrophase Colony-Simulating Factor and 3'-Azido-3'-Deoxythymidine Against Human Immunodeficiency Virus in vitro," Antimicrob. Agents Chemother. 31:1046-1050 (1987).
Hartshorn, K.L., et al., "Synergistic Inhibition of Human T-Cell Lymphotrophic Virus Type III Replication in vitro by Phosphonoformate and Recombinant .alpha.-A Interferon," Antimicrob. Agents Chemother. 31: 168-172 (1987).
Hartshorn, K.L., et al., Antimicrob. Agents Chemother. 30:189-191 (1987).
Hirsch, M.S., et al., "Treatment of Human Immunodeficiency Virus Infection," Antimicrob. Agents Chemother. 31: 839-843 (1987).
Hoffman, A.D., et al.; "Characterization of the AIDS-Associated Retrovirus Reverse Transcriptase and Optimal Conditions for its Detection in virons," Virology, 147: 326-335 (1985).
Hwang, B.C., et al., "A Point Mutation within a Conserved Region of the Herpes Simplex Virus DNA Polymerase Gene Confers Drug Resistance," J. Virol., 66: (1992) 1774-1776.
Im, G.J., et al., "Identification of the Amino Acid in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Pyrophosphate Binding of Antiviral Nucleoside Triphosphate Analogs and Phosphonoformate. Implications for Multiple Drug Resistance," Biochem. Pharmacol., 46: (1993) 2307-13.
Jackson, J.B., et al., "Rapid and Sensitive Viral Culture Method for Human Immunodeficiency Virus Type 1," J. Clin. Micro 26: (1988) 1416-1418.
Jacobo-Molina, A., et al., "Crystal Structure of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Complexed with Double-Strand DNA at 3.0 A resolution shows bent DNA," Proc. Natl. Acad. Sci. USA, 90: (1993) 6320-6324.
Jacobson, M.A., et al., "Effect of Foscarnet Therapy on Infection with Human Immunodeficiency Virus in Patients with AIDS," J. Infect. Dis., 158: (1988) 862-865.
Japour, A.J., et al., "Standardized Peripheral Blood Mononuclear Cell Culture Assay for Determination of Drug Susceptibilities of Clinical Human Immunodeficiency Virus Type 1 Isolates," Antimicrob. Agents Chemother. 37: (1993) 1095-01.
Klintmalm, G., et al., "Intravenous Foscarnet for the Treatment of Severe Cytomegalovirus Infection in Allograft Recipients," Scand. J. Infec. Dis. 17: 157-163 (1985).
Knox, K.K., et al., "Cytomegalovirus Isolate Resistant to Ganciclovir and Foscarnet from a Marrow Transplant Patient," Lancet, ii: (1991) 1292-1293.
Larder, B.A., "3'-Azido-3'-Deoxythymidine Resistance Suppressed by a Mutation Conferring Human Immunodeficiency Virus Type 1 Resistance to Nonnucleoside Reverse Transcriptase Inhibitors," Antimicrob. Agents Chemother., 36: (1992) 2664-2669.
Larder, B.A., et al., "Susceptibilities of Zidovudine-Susceptible and -Resistant Human Immunodeficiency Virus Isolates to Antiviral Agents Determined by Using a Quantitative Plaque Reduction Assay," Antimicrob. Agents Chemother., 34: (1990) 436-441.
Larder, BA, et al., "Site-Specific Mutagenesis of AIDS Virus Reverse Transcriptase," Nature, 327: (1987) 716-7.
Larder, B.A., et al., "Infectious Potential of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutants with Altered Inhibitor Sensitivity," Proc. Natl. Acad. Sci. USA, 86: (1989) 4803-7.
Larder, B.A., et al., "HIV with Reduced Sensitive to Zidovudine (AZT) Isolated During Prolonged Therapy," Science,. 243: 1731-1734 (1989).
Laskin, O.L., et al., "Ganciclovir for the Treatment and Suppression of Serious Infections Caused by Cytamegalovirus," Am. J. Med., 83:201-207 (1987).
Lin, T., et al., "Synthesis and Biological Activity of Several Amino Analogues of Thymidine," J. Med. Chem. 21:109-112 (1978).
Lowe, D.M., et al., "Mutational Analysis of Two Conversed Sequence Motifs in HIV-1 Reverse Transcriptase," FEBS Letters, 282: (1991) 231-234.
Mayers, D.L., et al., "Characterization of HIV Isolates Arising After Prolonged Zidovudine Therapy," J. Acquir. Immune Defic. Syndr. 5: (1992) 749-759.
Mellors, J.W., et al., "A Single Conservative Amino Acid Substitution in the Reverse Transcriptase of Human Immunodeficiency Virus-1 Confers Resistance to (1993) 11-16.
Mellors, J.W., "In vitro Selection and Molecular Characterization of Human Immunodeficiency Virus-1 Resistance to Non-Nucleoside Inhibitors of Reverse Transcriptase," Mol. Pharmacol., (1991) 41: 446-451.
Mitsuya, H., et al., "Strategies for the Antiviral Therapy in AIDS," Nature, 325:773-778 (1987).
Myers, G., et al., "Retroviruses and AIDS 1991: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences," Theoretical Biology and Biophysic Group, Los Alamos National Laboratory, Los Almos, NM, p. II-22.
Nguyen, M.H., et al., "Resistance of Human Immunodeficiency Virus Type 1 to Acyclic 6-Phenylselenenyl-and 6-Phenylthiopyrimidines," Antimicrob. Agents Chemother. 38: (1994) 2409-2414.
Oberg, B., "Antiviral Effects of Phosphonoformate (PFA, foscarnet sodium)," Pharmacol. Therap., 40: (1989) 213-85.
Oberg, B., "Antiviral Effects of Phosphonoformate (PFA, foscarnet sodium)," Pharmacol. Therap., 19:387-415 (1983).
Oberg, B., et al., "Clinical Use of Foscarnet (Phosphonoformate)," In E. DeClercq (ed.) Clinical Use of Antiviral Drugs, pp. 223-240 Martinus Nijhoff Publishing (1983).
Peden, K., et al., "The Characterization of Infectious Molecular Clones of HIV-1.sub.LAI, HIV-1.sub.MAL, and HIV-1.sub.ELI : Changes in Growth Properties on Passage is Tissue Culture," Virology 185: (1991) 661-672.
Pepose, J.S., et al., "Acquired Immune deficiency Syndrom. Pathogenic Mechanisms of Ocular Disease," Ophthalmology, 92:472-484 (1985
Eriksson Bertil F. H.
Schinazi Raymond F.
Aktiebolaget Astra
Drivas Dimitrios T.
Goldberg Jerome D.
Knowles Sherry M.
Scheibeler John
LandOfFree
Pharmaceutical composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1229203